Gresham Technologies (GHT)

Sector:

IT Services

Index:

techMARK

163.79p
   
  • Change Today:
      3.79p
  • 52 Week High: 163.79
  • 52 Week Low: 114.00
  • Currency: UK Pounds
  • Shares Issued: 83.87m
  • Volume: 2,356
  • Market Cap: £137.38m
  • RiskGrade: 80

Small caps round-up: Gresham Computing, Alliance Pharma, Young and Co's...

Date: Tuesday 10 Jul 2012

LONDON (ShareCast) - Gresham Computing has unveiled Australia and New Zealand Banking Group as its partner in a previously announced significant contract win. Under the deal Gresham will for a third time partner the bank, providing cash and information management solutions for corporate clients in an effort to increase visibility, control and efficiency in these areas. The bank said it believes the deal is the start of a long-term partnership for the two companies.

Alliance Pharma, a speciality pharmaceutical company, has said trading during the six months ended June 30th has been in line with management's expectations, with turnover of around £22m. The Hydromol produce continues to perform well, with growth of 28% over the first half of 2011. The firm said it is continuing to explore a number of acquisition opportunities, some of which are at a very advanced stage. The temporary suspension of the ImmuCyst product is expected to end in late 2013.

Young & Co's Brewery has said recent trading has improved significantly since the poor performance in the first seven weeks, as reported earlier in the year. Consequently managed house revenue for the first thirteen weeks was up 10.1%, and up 4.0% on a like-for-like basis. Managed house trading has benefited from a number of factors including the impact of last year's investments in new pubs, the addition of three sites transferred from tenancy, and strong trading during the Diamond Jubilee celebrations.

The firm is anticipating a strong period of trading during the Olympics and it remains confident in its strategy, believing well-invested estate and management focus on growth should continue to drive superior like-for-like performance.

Leni Oil & Gas has completed the first five planned workovers on the Goudron Field and has confirmed that an average production potential per well of 10 barrels of oil per day (bopd) is achievable from existing wells. The programme was completed in 35 days at a cost of around $50,000. The upcoming transfer of the incremental production services contract to Goudron E&P will trigger payment of outstanding considerations to Cameron Oil and Gas and Sorgenia International, which the company is intending to finance out of the proceeds of the sale of the Spanish assets. The transfer is intended to expand the workover programme and to commence detailed planning for new infill wells.

Sphere Medical, a diagnostic product developer, has received an order for cardiopulmonary bypass monitors and microanalyser consumables for delivery in the fourth quarter of 2012 from Sorin Group. The order represents the first sale for the development and supply agreement relating to the CPB product which will be used by Sorin Group in market assessment studies which are scheduled to commence later this year. Sphere described the sale as an "important milestone" which demonstrates its ability to partner its products with global medical device companies.

NR

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GHT Market Data

Currency UK Pounds
Share Price 163.79p
Change Today 3.79p
% Change 2.37 %
52 Week High 163.79
52 Week Low 114.00
Volume 2,356
Shares Issued 83.87m
Market Cap £137.38m
RiskGrade 80

GHT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
97.36% below the market average97.36% below the market average97.36% below the market average97.36% below the market average97.36% below the market average
85.54% below the sector average85.54% below the sector average85.54% below the sector average85.54% below the sector average85.54% below the sector average
Price Trend
47.30% above the market average47.30% above the market average47.30% above the market average47.30% above the market average47.30% above the market average
26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average
Income
70.89% below the market average70.89% below the market average70.89% below the market average70.89% below the market average70.89% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average
Growth
72.20% above the market average72.20% above the market average72.20% above the market average72.20% above the market average72.20% above the market average
60.47% above the sector average60.47% above the sector average60.47% above the sector average60.47% above the sector average60.47% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GHT Dividends

  Latest Previous
  Interim Final
Ex-Div 09-May-24 27-Apr-23
Paid 10-Jun-24 26-May-23
Amount 0.75p 0.75p

Trades for 01-May-2024

Time Volume / Share Price
08:28 2,356 @ 162.00p

GHT Key Personnel

CEO Ian Manocha

Top of Page